ALX Oncology is cutting two studies of its anti-CD47 drug evorpacept after it failed to show substantial efficacy.
In its second-quarter report Thursday afternoon, ALX said that it was winding down studies of evorpacept in acute myeloid leukemia (AML) and its precursor disease, myelodysplastic syndromes (MDS). In 45 patients in…
Click here to view original post
